Parker Waichman LLP has filed a lawsuit alleging that Takeda’s diabetes drug Actos (pioglitazone) caused bladder cancer. June 25, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Tennessee man who developed bladder cancer, allegedly due to Actos...District Court for the Western District of Louisiana (Case No. Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Co. as Defendants. The case is currently pending in the multidistrict litigation, as part of In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No...Parker, co-founder of Parker Waichman LLP, has been appointed to the Plaintiffs’ Steering Committee.[http://www.lawd.uscourts.gov/MDL2299; http://www.lawd.uscourts.gov/MDL2299/html/news.html
According to the complaint, the Plaintiff took Actos from about 2007 to 2011 and developed bladder cancer in June 2008. The lawsuit alleges that Actos caused severe mental and physical pain and suffering, past and future permanent injuries and emotional distress, economic loss due to medical expenses and living related expenses as a result of a new lifestyle on behalf of the Plaintiff. The suit also alleges loss of consortium on behalf of the Plaintiff’s spouse.
Takeda and Eli Lilly gained clearance for Actos in 1999 as a type 2 diabetes medication. According to the lawsuit, Takeda declared the collaboration to be over in April 2006. Type 2 diabetes is a disease where the body either fails to produce enough insulin, or does not use it efficiently. As a result, patients are unable to properly metabolize glucose for energy. According to the complaint, Actos is part of a class of drugs known as thiazolidinediones (TZDs), which is meant to increase the body’s sensitivity to insulin. But the lawsuit alleges that Actos is defective, and poses serious risks of bladder cancer to its users. [diabetes.org/diabetes-basics/type-2/]
The lawsuit states that if the Defendants’ had properly warned of the risks, then the Plaintiff would have never taken Actos and suffered the subsequent complications. In particular, the suit points out that the Defendants failed to warn about the increased risk associated with using Actos for one year or more...Food and Drug Administration (FDA) last June in a Safety Announcement. The agency had said that users were at an increased risk of 40 percent after one year compared to non-users, and subsequently ordered a label update. In a previous announcement issued in 2010, the FDA had stated that the risk was apparent after two years of exposure. [http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm; http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm
This April, Canadian authorities also updated the safety label on Actos to address the increased risk of bladder cancer. [hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2012/actos_3_pc-cp-eng.php]
Last June, France and Germany stopped the use of Actos altogether, after data from the French Medicines Agency found a significant link. According to the complaint, researchers found an increased risk of bladder cancer in male patients who used Actos for at least one year. Most recently, a Canadian study published in the British Medical Journal revealed a two-fold increased risk after two years of use. [bmj.com/content/344/bmj.e3500?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bmj%2Frheumatology+%28Latest+Rheumatology+articles+from+the+BMJ%29]
Parker Waichman LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm's Actos injury page at http://www.yourlawyer.com. For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9633386.htm